Shenwan Hongyuan Securities·2026-01-25 12:44Investment Rating - The report indicates a cautious outlook on the pharmaceutical sector, with a focus on investment opportunities in the CXO segment and AI pharmaceutical development [2][3]. Core Insights - The pharmaceutical sector's performance has been mixed, with the Shenwan Pharmaceutical and Biological Index declining by 0.4% while the Shanghai Composite Index rose by 0.84% [4][6]. - The report highlights the ongoing transformation in China's pharmaceutical retail industry, emphasizing the shift from traditional drug sales to comprehensive health services, supported by government initiatives [13][14]. - New drug development remains active, with several significant clinical trial applications and promising results from innovative therapies, particularly in oncology and AI-driven drug discovery [15][16][17]. Market Performance - The Shenwan Pharmaceutical and Biological Index ranked 27th among 31 Shenwan first-level sub-industries, with a current overall valuation of 30.3 times earnings, placing it 12th among all first-level industries [4][6]. - Various sub-sectors showed differing performance, with raw materials (+2.4%) and offline pharmacies (+9.7%) performing well, while medical research outsourcing (-4.0%) and chemical preparations (-1.7%) faced declines [6][8]. Recent Key Events - The report notes the significant population dynamics in China, with a total population of approximately 1.40489 billion by the end of 2025, which continues to support economic growth [12]. - The Ministry of Commerce and other departments have issued guidelines to promote high-quality development in the pharmaceutical retail sector, focusing on enhancing service capabilities and optimizing industry structure [13][14]. - Several companies, including BaiLi Tianheng and Moderna, have made strides in drug development, with notable advancements in cancer therapies and AI applications in pharmaceuticals [15][16][17]. Company Dynamics - The report identifies several companies with promising performance forecasts for 2025, including WuXi AppTec, Kanglong Chemical, and Tigermed, highlighting their potential as investment targets [23][26]. - The AI healthcare platform OpenEvidence successfully raised $250 million in Series D funding, reflecting strong growth and increasing adoption among healthcare professionals [23][24].